Upstream / Downstream

Explore pathways related to this product.

Our U.S. Offices Are Closed

Our U.S. offices are closed in observance of Thanksgiving. We will reopen on Monday, December 1st.

Thank you for your patience.

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Product Includes Quantity Applications Reactivity MW(kDa) Isotype
Phospho-HER2/ErbB2 (Tyr1248) Antibody 2247 40 µl
Western Blotting
H 185 Rabbit 
Phospho-HER2/ErbB2 (Tyr1221/1222) (6B12) Rabbit mAb 2243 40 µl
Western Blotting Immunohistochemistry
H 185 Rabbit IgG
HER2/ErbB2 (D8F12) XP® Rabbit mAb 4290 40 µl
Western Blotting Immunohistochemistry
H 185 Rabbit IgG
Anti-rabbit IgG, HRP-linked Antibody 7074 100 µl
Western Blotting
All Goat 

Product Description

The Phospho-HER2/ErbB2 Antibody Sampler Kit provides an economical means to evaluate the activation status of HER2/ErbB2, including the phosphorylation of Tyr1248 and Tyr1221/1222. The control HER2/ErbB2 antibody is also included. The kit contains enough primary antibodies to perform four Western blot experiments per primary antibody.


Specificity / Sensitivity

Each phospho-HER2/ErbB2 antibody recognizes only the phosphorylated form of HER2/ErbB2 at the indicated sites. The control HER2/ErbB2 receptor antibody recognizes both phosphorylated and nonphosphorylated forms of HER2/ErbB2.


Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr1248. Polyclonal antibodies are purified by protein A and peptide affinity chromatography. Monoclonal antibodies are produced by immunizing animals with synthetic peptides corresponding to residues surrounding tyrosines 1221/1222 and residues near the amino terminus of human ErbB2 protein.

The ErbB2 (HER2) proto-oncogene encodes a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity (1). While ErbB2 lacks an identified ligand, ErbB2 kinase activity can be activated in the absence of a ligand when overexpressed and through heteromeric associations with other ErbB family members (2). Amplification of the ErbB2 gene and overexpression of its product are detected in almost 40% of human breast cancers (3). Binding of the c-Cbl ubiquitin ligase to ErbB2 at Tyr1112 leads to ErbB2 poly-ubiquitination and enhances degradation of this kinase (4). ErbB2 is a key therapeutic target in the treatment of breast cancer and other carcinomas and targeting the regulation of ErbB2 degradation by the c-Cbl-regulated proteolytic pathway is one potential therapeutic strategy. Phosphorylation of the kinase domain residue Tyr877 of ErbB2 (homologous to Tyr416 of pp60c-Src) may be involved in regulating ErbB2 biological activity. The major autophosphorylation sites in ErbB2 are Tyr1248 and Tyr1221/1222; phosphorylation of these sites couples ErbB2 to the Ras-Raf-MAP kinase signal transduction pathway (1,5).


1.  Muthuswamy, S.K. et al. (1999) Mol Cell Biol 19, 6845-57.

2.  Qian, X. et al. (1994) Proc Natl Acad Sci USA 91, 1500-4.

3.  Dittadi, R. and Gion, M. (2000) J Natl Cancer Inst 92, 1443-4.

4.  Klapper, L.N. et al. (2000) Cancer Res 60, 3384-8.

5.  Kwon, Y.K. et al. (1997) J Neurosci 17, 8293-9.


Entrez-Gene Id 2064
Swiss-Prot Acc. P04626


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 5,675,063.